aug2015 deanna church analytical validation

19
© 2014 Personalis, Inc. All rights reserved. Pioneering Genome-Guided Medicine Perspectives on analytical validity Deanna M. Church, PhD Senior Director of Genomics and Content Personalis, Inc

Upload: genomeinabottle

Post on 18-Jan-2017

879 views

Category:

Healthcare


0 download

TRANSCRIPT

Page 1: Aug2015 deanna church analytical validation

© 2014 Personalis, Inc. All rights reserved.

Pioneering Genome-Guided Medicine

Perspectives on analytical validityDeanna M. Church, PhD Senior Director of Genomics and Content Personalis, Inc

Page 2: Aug2015 deanna church analytical validation

2

Disclosure

I work for Personalis, Inc. A company that provides whole genome and augmented whole exome sequencing, analysis services and clinical interpretation services.

Page 3: Aug2015 deanna church analytical validation

3

•  What RMs would be useful for analytic validation of somatic variants? •  How does targeted sequencing differ from WGS in terms of analytic

validation needs? •  What’s the role of benchmarking data sets in validating bioinformatics? •  Is there a role for “benchmark” or “reference” pipelines? •  What GIAB products other than RMs should we produce?

–  Would a product like a whitepaper outlining the common pitfalls in analytic validation for NGS be a good product?

–  Is there a need for other process controls (e.g., FFPE-embedded, mixtures, etc.)?

–  What role can spike-ins play in validation? What would they look like? For somatic mutations? For germline mutations?

•  What are the most specific knowledge gaps in how to do analytic  validation for NGS?

Page 4: Aug2015 deanna church analytical validation

© 2014 Personalis, Inc. All rights reserved.

ACE Clinical Exome™ with Enhanced Diagnostic Yield

Assay development and evaluation

Page 5: Aug2015 deanna church analytical validation

5

Deficits in Coverage in a Key GeneVariants in RPGR cause ~80% of X-linked retinitis pigmentosa

Previously described

variants

Depth Coverage Plot of RPGR Dark blue represents coverage at 1 standard deviation from mean

>20x Coverage (required to call heterozygous SNVs and indels accurately)

* Coverage plots are representative sequence coverage based upon N=16

Page 6: Aug2015 deanna church analytical validation

6 >20x Coverage (required to call heterozygous SNVs and indels accurately)

Previously described

variants

Depth Coverage Plot of RPGR Dark blue represents coverage at 1 standard deviation from mean

* Coverage plots are representative sequence coverage based upon N=16

Assay improvementVariants in RPGR cause ~80% of X-linked retinitis pigmentosa

Enhanced Exome

Standard Exome p.Glu809Glyfs*25

Page 7: Aug2015 deanna church analytical validation

7

Coverage in medically interpretable genes

Percent bases with >20X local high quality coverage depth: finishing metric

Perc

ent f

inis

hed

exon

s

coding non-coding

Augmented exome

Exome 1

Exome 2 Exome 3

Exome 4

31X PCR-free WGS

Patwardhan et al., Genome Medicine 2015

Page 8: Aug2015 deanna church analytical validation

8

Identifying low frequency allelesACE Exome 12G

ACE Cancer Panel 12G

WGS 100G (30x)

TP53

Page 9: Aug2015 deanna church analytical validation

9

Breakdown

• How does targeted sequencing differ from WGS in terms of analytic validation needs?

Targeted sequencing is an important part of improved performance. The analytical needs are similar, but the reference data must contain variants in all parts of the genome, even the hard ones.

Page 10: Aug2015 deanna church analytical validation

10

Breakdown

• Is there a role for “benchmark” or “reference” pipelines? This is really of limited utility as custom assay development often has custom informatics.

Page 11: Aug2015 deanna church analytical validation

11

Breakdown

• What are the most specific knowledge gaps in how to do analytic validation for NGS? Increased transparency on exact intervals being tested and metrics based on variant type and allelic fraction.

Page 12: Aug2015 deanna church analytical validation

© 2014 Personalis, Inc. All rights reserved.

ACE Clinical Exome™ with Enhanced Diagnostic Yield

Cancer clinical validation study

Page 13: Aug2015 deanna church analytical validation

13

ACE Cancer Panel CLIA Validation Results

ACE Cancer Panel Performance Specifications

Sensitivity Base Substitutions >99% MAF ≥ 5%

Indels >99% MAF ≥ 10%

CNAs 97% tumor content ≥ 20%

Gene Fusions >99%

Specificity >99%*

Typical Median Depth >500X

Sample Types Fresh Frozen or FFPE Tumor Samples ≥ 20% Tumor

* Based on Base substitutions and Indels, others pending

Page 14: Aug2015 deanna church analytical validation

14

Breakdown

• What are the most specific knowledge gaps in how to do analytic validation for NGS? Increased transparency on exact intervals being tested and metrics based on variant type and allelic fraction.

Page 15: Aug2015 deanna church analytical validation

© 2014 Personalis, Inc. All rights reserved.

ACE Clinical Exome™ with Enhanced Diagnostic Yield

Real life samples

Page 16: Aug2015 deanna church analytical validation

16

FFPE sample challenge

Large range of performance for FFPE samples

40 50 60 70 80 90

100

MC

C43

7_D

NA

MC

C43

8_D

NA

DN

AS

EQ

2_tu

mM

TSC

C_D

NA

SA

M20

3709

21 5

S06

_417

75_A

1 4 A

02-2

1A

S09

_353

7_A

2 C

13-2

710A

1 O

NY

X88

78

JK-3

S

AM

2037

0921

P

harm

B

S04

_429

81_A

1 S

14_1

7554

_B2

Pha

rmA

03-2

2957

A1

PS

13_9

876_

A8

PR

13_2

69_5

2A

GLU

T1_N

orm

oxS

06_2

1760

_A2

SA

M20

3709

37

B1

PR

13_2

69_1

3A

JK-9

P

R13

_269

_31A

JK

-11

05-2

9776

34

67B

_DN

A 14

-021

82A

16

SA

M20

3709

20

13

JK-8

14

0020

3252

13

2600

6032

S

AM

2037

0924

A

Z_D

NA

_1

AZ_

DN

A_3

11

06-0

91-2

01B

-A

Z_D

NA

_10

AZ_

DN

A_7

S

AM

2037

0932

A

Z_D

NA

_8

% mapped

% mapped

20 30 40 50 60

MC

C43

7_M

CC

438_

DN

AS

EQ

2M

TSC

C_D

SA

M20

37 5 S

06_4

177 4

A02

-21A

S

09_3

537

C13

-271

0O

NY

X88

7JK

-3

SA

M20

37P

harm

B

S04

_429

8S

14_1

755

Pha

rmA

03-2

2957

PS

13_9

87P

R13

_269

GLU

T1_N

S06

_217

6S

AM

2037 B

1 P

R13

_269

JK-9

P

R13

_269

JK-1

1 05

-297

76

3467

B_D

14-0

2182

SA

M20

37 13

JK-8

14

0020

3213

2600

60S

AM

2037

AZ_

DN

A_

AZ_

DN

A_

1106

-091

-A

Z_D

NA

_A

Z_D

NA

_S

AM

2037

AZ_

DN

A_

Qmap

Qmap

Page 17: Aug2015 deanna church analytical validation

17

RT 37C 45C

3 day 1 day 3 day 1 day 3 day 1 day

1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6

1.  0% PBS 2.  20% PBS 3.  40% PBS 4.  60% PBS 5.  80% PBS 6.  100% PBS

Genomic DNA Extracted from FFPE samples

Page 18: Aug2015 deanna church analytical validation

18

RT 37C 45C

3 day 1 day 3 day 1 day 3 day 1 day

1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6

1.  0% PBS 2.  20% PBS 3.  40% PBS 4.  60% PBS 5.  80% PBS 6.  100% PBS

DNA Library Generated from FFPE samples

Page 19: Aug2015 deanna church analytical validation

19

Breakdown

• What RMs would be useful for analytic validation of somatic variants? More RMs that represent the variable sample quality seen in real clinical specimens.